VFS
ANIP icon

VSR Financial Services’s ANI Pharmaceuticals ANIP Stock Holding History

VSR Financial Services’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,951
Closed -$245K – 574
2015
Q2 		$245K Buy
+3,951
New +$235K 0.03% 485

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VSR Financial Services's ANIP Position: Q3 2015 in Review

VSR Financial Services sold out of ANI Pharmaceuticals (ANIP) in Q3 2015, closing a stake of 3,951 shares — an estimated $245K sold.

VSR Financial Services first reported a position in ANIP in Q2 2015 and held it in 1 quarter. The position peaked at $245K in Q2 2015. 121 funds tracked by Wall St. Rank hold ANIP as of Q3 2015.

  • VSR Financial Services reported no remaining ANI Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • VSR Financial Services sold 3,951 ANI Pharmaceuticals shares in Q3 2015, an estimated $245K.
  • VSR Financial Services first reported a position in ANI Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • VSR Financial Services's ANI Pharmaceuticals position peaked at $245K in Q2 2015.
  • 121 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2015.

Based on VSR Financial Services's 13F filing for Q3 2015, filed 26 Oct 2015.